Related Experiment Video
Updated: Oct 4, 2025
Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
Intra-tracheal delivery of mesenchymal stem cell-conditioned medium ameliorates pathological changes by inhibiting
Rana Keyhanmanesh1, Fatemeh Khodamoradi2, Reza Rahbarghazi3,4
1Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Insights
Mesenchymal stem cell-derived secretome (MSC-CM) alleviates asthma by reducing airway inflammation and regulating apoptosis in lung tissue. This study investigated MSC-CM
Area of Science:
- Pulmonary Medicine
- Regenerative Medicine
- Cell Biology
Background:
- Asthma is a prevalent inflammatory lung disease in children.
- Investigating apoptosis in asthma is crucial for understanding disease mechanisms.
- Mesenchymal stem cells (MSCs) and their secretome show therapeutic potential.
Purpose of the Study:
- To evaluate the effect of rat mesenchymal stem cells (MSC-CM)-derived secretome on apoptosis in pediatric asthma.
- To analyze changes in key gene expressions related to T-helper cell differentiation and apoptosis.
- To assess the impact of MSC-CM on inflammatory markers and lung pathology.
Main Methods:
- Male Wistar rats were divided into control, sensitized (asthma model), and MSC-CM treated groups.
- MSC-CM was administered intratracheally.
- Gene expression analysis (T-bet, GATA-3, Bax, Bcl-2, Caspase-3), H&E staining for pathology, and ELISA for TNF-α were performed.
Main Results:
- MSC-CM treatment increased T-bet expression and decreased GATA-3 expression in asthmatic rats.
- Levels of TNF-α in bronchoalveolar lavage fluid (BALF) were significantly reduced post-MSC-CM administration.
- MSC-CM altered apoptosis-related gene expression, decreasing Bax and Caspase-3, while increasing Bcl-2.
Conclusions:
- Direct administration of MSC-CM effectively alleviates airway inflammation in asthma.
- MSC-CM appears to exert its therapeutic effect by downregulating apoptotic cell death in the pulmonary niche.
- These findings highlight MSC-CM as a potential therapeutic agent for managing asthma.
Background:
Asthma, an inflammatory illness of the lungs, remains the most common long-term disease amongst children. This study tried to elaborate the status of apoptosis in asthmatic pulmonary niche after the application of rat mesenchymal stem cells (MSC-CM)-derived secretome.
Methods And Results:
Here, we randomly allocated male Wistar rats into three groups (n = 8); Control animals were intratracheally given 50 μl vehicle. In control-matched sensitized rats, 50 μl normal saline was used. In the last group, 50 μl MSC-CM was applied. Two-week post-administration, transcription of T-bet, GATA-3, Bax, Bcl-2 and Caspase-3 was measured by gene expression analysis. Pathological injuries were monitored using H&E staining. The BALF level of TNF-α was measured using ELISA assay. In asthmatic rats received MSC-CM, the expression of T-bet was increased while the level of GATA-3 decreased compared to the S group (p < 0.05). Levels of BALF TNF-α were suppressed in asthmatic niche after MSC-CM administration (p < 0.05). Compared to the asthmatic group, MSC-CM had potential to alter the expression of apoptosis-related genes in which the expression of Bax and Caspase 3 was decreased and the expression of pro-survival factor, Bcl-2 increased (p < 0.05).
Conclusion:
Our data notified the potency of direct administration of MSC-CM in the alleviation of airway inflammation, presumably by down regulating apoptotic death in pulmonary niche.
More Related Videos
04:21A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease
Published on: August 4, 2021
09:02Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment
Published on: June 28, 2018